AdhereBio LLC has recently filed a Form D, indicating its intent to conduct an exempt offering of securities. This filing, dated October 26, 2026, is a critical step for the company as it seeks to raise capital through private placements.

AdhereBio LLC is based in Fort Lauderdale, Florida, and operates under the entity type "other." The company has been actively engaging with investors to secure funding, and this filing reflects its ongoing efforts to expand its financial resources.

The filing states, "Effectiveness Date: 2026-10-26," which confirms that the offering is set to proceed immediately. However, details regarding the amount being raised or the specific terms of the offering were not available in the SEC filing.

This move may impact various stakeholders, including potential investors and competitors in the biotech and healthcare sectors. As AdhereBio explores new financing avenues, other companies may need to reconsider their fundraising strategies to stay relevant in a competitive landscape.

The filing does not say what happens next, leaving the future steps of this offering open-ended as the company navigates its fundraising journey.

Company Details

AdhereBio LLC has a Central Index Key (CIK) number of 0002160633, which is used to identify the company in SEC filings. The company was incorporated in Delaware and has an Employer Identification Number (EIN) of 432308499. Its fiscal year ends on December 31.

Mailing and Business Address

The company’s mailing and business address is 215 N New River Dr E Ste 2820, Fort Lauderdale, FL 33301. This location serves as the primary point of contact for potential investors and stakeholders.

"Effectiveness Date: 2026-10-26" indicates that the company is ready to move forward with its fundraising efforts without delay.

Filing Specifics

The SEC filing is categorized under Act 33, with a file number of 021-602502 and a film number of 261484846. This classification is important for regulatory compliance and tracking purposes.

While the filing provides essential information about the offering, it does not disclose the amount being raised or the specific terms of the securities being offered, leaving some details about the offering still unclear.